aflibercept injection (VEGF Trap-Eye, BAY86-5321)

BIOLOGICAL2 trials

Sponsors

Regeneron Pharmaceuticals

Conditions

Macular Degeneration

Phase 2

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

CompletedNCT00320788

Regeneron PharmaceuticalsMacular Degeneration

Start: 2006-04-30End: 2008-08-31Updated: 2012-03-01

Phase 3

Vascular Endothelial Growth Factor VEGF Trap-Eye:Investigation of Efficacy and Safety in Wet Age-Related Macular Degeneration(AMD)

CompletedNCT00509795

Regeneron PharmaceuticalsMacular Degeneration

Start: 2007-08-31End: 2011-07-31Updated: 2012-12-28

Related Papers

Changes in neovascular activity following fixed dosing with an anti-vascular endothelial growth factor agent over 52 weeks in the phase III VIEW 1 and VIEW 2 studies

British Journal of Ophthalmology2019-12-115 citations

Improvement in vision-related function with intravitreal aflibercept: data from phase 3 studies in wet age-related macular degeneration.

2014-11-0639 citations